Confirmed: No Slowing of Parkinson's Prog... - Cure Parkinson's
Confirmed: No Slowing of Parkinson's Progression With Rasagiline
Here is a better link: movementdisorders.onlinelib...
Conclusions
We found no evidence that 1 mg/day rasagiline has a disease-modifying effect in PD over 1 year. We found pSN free-water increased over 1 year, and baseline free-water relates to clinical motor progression, demonstrating the importance of diffusion imaging parameters for detecting and predicting PD progression. © 2021 International Parkinson and Movement Disorder Society
So, correct me if I’m wrong, but there are no medications which are believed to slow progression now? The
Hi Dap1948:
Depending on who you ask, that was true before this current research. 10 years ago the US FDA concluded that "there was insufficient evidence of a disease modifying benefit with rasagiline." [see page 114 in Dr Ahlskog's book]
Too bad. I remember we had more hope when my husband started Azilect over a decade ago.
Not the greatest news, but better to know and move on....
I’m sure this won’t stop those who anecdotally feel it’s helping them already from continuing to take..
As I understand it, this research says nothing about the symptomatic benefits of rasagiline.
Rasagiline is a MAO-B inhibitor which means that it makes dopamine last longer. A dose of 1 mg of rasagiline has, approximately, a levodopa equivalent dose of 100 mg.
Rasagiline has the useful feature that its half-life is long enough for a daily dose to give an almost constant benefit. Roughly speaking, C/L which has a short half-life of about 90 minutes, gives a period of effectiveness of about 4 hours. Equating the area under the curve, implies that rasagiline gives a continuous benefit equivalent to 100 x 4 / 24 = 16 mg of levodopa. For many this is not noticeable, but it is still there, working in the background.
Unfortunately, the most rasagiline that can be taken per day is about 1 mg.
I was on for a short time as it caused me cardiac problems. I was advised to discontinue it.